tbuckley/cabot-search huggingface dataset:
Use of germline polymorphisms in VEGF to predict tumor response and progression-free survival in non-small cell lung cancer (NSCLC) patients treated with sorafenib: Subset pharmacogenetic analysis of Eastern Cooperative Oncology Group (ECOG) trial E2501.
Authors: W. Zhang, J. Lee, J. H. Schiller, D. P. Carbone, C. H. Chung, H. Lenz
Journal: Journal of Clinical Oncology (2010)

7607 Background: E2501 was a randomized discontinuation phase II study of sorafenib (S) versus placebo (P) in patients (pts) with metastatic NSCLC who have failed at least two prior chemotherapy regimens. Recent studies suggested that polymorphisms associated with angiogenesis pathway can predict clinical outcome to anti-VEGF based therapies in advanced breast cancer (E2100) and advanced NSCLC (E4599) pts. We tested the hypothesis that gene polymorphisms (VEGF, EGF, EGFR, IL-8, CXCR2, COX-2, KDR, ICAM1, FGFR4) may predict clinical outcome in patients enrolled in E2501. Methods: During Step 1, 333 pts received 400 mg of S po twice daily for 2 cycles (2 months). Responding pts (n = 12) on Step 1 continued on S; progressing pts went off study, and pts with stable disease (n = 107) were randomized to P or S (Step 2). PCR-RFLP assays were performed on genomic DNA extracted from plasma of patients. There were 88 plasma samples available for analysis: these included 76 pts from Step 1 and 18 (14 on S and 4 on P) from Step 2. Results: Patients with CC genotype for VEGF1498 had significantly lower disease control rate (DCR) (n = 22, 22.7%) compared with TT genotype (n = 25, 56%), (p = 0.036). Patients harboring any C allele of VEGF 1498 (CC+CT) had a worse DCR compared with TT genotype (26% vs 56%) (p = 0.021). VEGF634 and VEGF1498 showed significant differences in PFS among their three genotypes (p = 0.036 and p = 0.025, respectively). Patients on Step 2 receiving S with GG/GC (n = 6/4) VEGF634 genotypes tended to have shorter PFS (median = 1.7-2.8 mos) compared with VEGF634 CC genotype (n = 2, median = 7.7 mos) (p = 0.23). Patients with VEGF1498 CC genotype had significantly longer PFS (n = 4, median = 7.5 mos) compared with CT genotype (n = 2, median = 1.7 mos) (p = 0.018), but no difference with TT genotype (n = 7, median = 2.8 mos) (p = 0.60). No significant differences were observed among the other genes tested. Conclusions: Our preliminary results suggest polymorphisms in VEGF may predict DCR and PFS in NSCLC pts treated with sorafenib. Larger prospective trials to validate these findings are warranted. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer Bayer
P167 A ‘Virtual’ Lung Nodule Clinic: A novel approach to improve efficiency and accuracy of indeterminate lung nodule surveillance: Abstract P167 Table 1
Authors: J Thomas, S Grundy
Journal: Thorax (2015)

<h3>Background and objectives</h3> With increasing use and fidelity of CT scans the workload relating to surveillance of indeterminate lung nodules is ever increasing and is burdensome in terms of out-patients appointments and/or clinical administrative time. In July 2014 we established a 'virtual nodule clinic' (VNC) for reviewing indeterminate lung nodules. A proforma within our hospital electronic patient record is completed which automatically generates written communication for both the patient and the GP informing of the findings of the latest CT result and any follow-up required. The patients are not seen in clinic unless they request. The clinic template allows review of 40 cases per session. The objectives of this study are to review the impact of the VNC on concordance with Fleischner guidelines and timeliness of communication of results. <h3>Methods</h3> We retrospectively reviewed 50 consecutive nodule follow-up scans performed in November 2013 prior to establishment of VNC and 49 consecutive cases reviewed in VNC in November 2014. Concordance with Fleischner guidelines and date from CT scan to patient/GP being informed was reviewed. <h3>Results</h3> Demographics were similar between groups. The VNC has improved concordance with Fleischner guidelines in lung nodule surveillance by 40%. Prior to the VNC, 52% of patients had surveillance concordant with Fleischner guidelines. Following the introduction of the VNC, 92% of patients had follow-up concordant with Fleischner guidelines. Median time from the date of CT scan to the patient/GP being informed of CT results was 5 weeks. None of the cases reviewed in VNC contacted us to request a face to face consultation despite this being offered within the written communication to patients. <h3>Conclusion</h3> The introduction of a virtual nodule clinic has significantly improved concordance with published guidelines for radiological follow-up of indeterminate lung nodules. It has also allowed a significant reduction in the number of 'unnecessary' out-patient appointments within the lung cancer service. VNC ensures effective and timely communication of scan results to patients and GPs.
Population Based Study of Cytogenetic Abnormalities in Addition to Philadelphia (Ph) Chromosome in Patients with Chronic Myeloid Leukaemia (CML) and Impact on Survival
Authors: Jo Tomlins, Nick Telford, Mike Dennis, Tim Somervaille, Adrian Bloor, Jim Cavet, Mike Green, Sven Armin Sommerfeld, John Murray, Samar Kulkarni
Journal: Blood (2014)
Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma
Authors: Su Joa Ahn, Jeong Min Lee, Dong Ho Lee, Sang Min Lee, Jung-Hwan Yoon, Yoon Jun Kim, Jeong-Hoon Lee, Su Jong Yu, Joon Koo Han
Journal: Journal of Hepatology (2016)
Food Industry Funding of Nutrition Research
Authors: Marion Nestle
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma
Authors: Takaaki Beppu, Kazunori Terasaki, Toshiaki Sasaki, Yuichi Sato, Makiko Tomabechi, Kenichi Kato, Makoto Sasaki, Kuniaki Ogasawara
Journal: Clinical Nuclear Medicine (2016)

Normalization of tumor vasculature after administering bevacizumab (BEV) makes assessment of therapeutic response using MRI difficult. The aim of this study was to clarify whether PET with C-methyl-L-methionine (MET-PET) would supplement MRI assessing of response after initiating BEV in glioblastoma.Twenty patients with recurrent glioblastoma were treated with biweekly BEV plus temozolomide. Both MRI and MET-PET were performed before treatment (baseline) and at 4 and 8 weeks after starting treatment. Results on MRI (response or nonresponse) were compared with those on MET-PET, with response defined as a tumor-to-normal brain ratio of SUV (SUVT/N) of less than 1.6. Progression-free survival (PFS) was compared between responders and nonresponders on MRI alone and MET-PET alone. Progression-free survival was also compared between patients showing response on both MRI and MET-PET and patients showing response on MRI but nonresponse on MET-PET at each time point.PFS was significantly longer in responders than nonresponders on both MRI at 4 and 8 weeks and MET-PET at 8 weeks, whereas MET-PET at 4 weeks provided no information regarding outcomes. Combined assessment with MRI and MET-PET at 4 weeks was not provide predictive of PFS, whereas patients showing response on both modalities (true responders) at 8 weeks exhibited significantly longer PFS than did patients showing response on MRI but nonresponse on MET-PET (pseudoresponders).Combined assessment with MRI and MET-PET at 8 weeks can differentiate true responders who are predicted to show more favorable prognosis from pseudoresponders.
Mechanical Thrombectomy for Stroke
Authors: Jonathan M. Coutinho
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
In-host adaptation and acquired triazole resistance in Aspergillus fumigatus : a dilemma for clinical management
Authors: Paul E Verweij, Jianhua Zhang, Alfons J M Debets, Jacques F Meis, Frank L van de Veerdonk, Sijmen E Schoustra, Bas J Zwaan, Willem J G Melchers
Journal: The Lancet Infectious Diseases (2016)
P119 Responsiveness of the CAT (COPD Assessment Tool) in a stable and post exacerbation pulmonary rehabilitation population: Abstract P119 Table 1.
Authors: EJL Chaplin, EJL Chaplin, M Gibb, L Sewell, S Singh, S Singh
Journal: Thorax (2013)

<h3>Introduction</h3> The CAT is an eight item questionnaire used to assess health status. It has previously been used in stable COPD and non COPD patients (Kon <i>et al</i>, 2012) and as an outcome measure for pulmonary rehabilitation (PR) in the short term in a stable population (Dodd <i>et al</i>, 2012). However the CAT has not been used in a post exacerbation rehabilitation programme. <h3>Aim</h3> The aim of this study was to investigate whether there were any differences in response to the CAT between stable and post exacerbation patients undertaking rehabilitation. <h3>Methods</h3> Patients attending a 7 week out patient PR programme were given a CAT questionnaire pre and post rehabilitation. Patients included were diagnosed with COPD and were either from the stable waiting list or patients who had been referred to PR following a hospital admission for exacerbation of COPD in the last 6 weeks. <h3>Results</h3> 200 consecutive patients completed the CAT questionnaire -125 stable patients [74 male, MRC 3 (IQR 3–4), mean (SD) age 71.1 ( ± 8.9) years, FEV<sub>1</sub> 1.39L ( ± 0.6), BMI 28.5 ( ± 6.7)] and 75 post exacerbation patients [23 male, MRC 4 (IQR 3–5), mean (SD) age 70.6 ( ± 8.6) years, FEV<sub>1</sub> 1.16L ( ± 0.5), BMI 25.8 ( ± 7.3)]. There was a significant difference in baseline characteristics (BMI, FEV<sub>1</sub> and MRC) between the groups ( p = 0.05). A statistically significant difference between the stable and post exacerbation patient groups CAT score pre rehabilitation (p = 0.05) was observed. However there was no significant difference in post rehabilitation CAT scores (p = 0.12) and the change in CAT scores between the 2 groups (p = 0.63). There was a significant difference between the groups’ pre and post walking tests. The improvement in the ESWT (endurance shuttle walking test) in the stable group was greater (p&lt; 0.05). <h3>Conclusion</h3> Post exacerbation PR patients have a worse CAT score prior to PR when compared to a stable PR population but both groups make improvements in CAT following completion of PR.
Influence of Preexisting Invasive Aspergillosis on Allo-HSCT Outcome: A Retrospective EBMT Analysis from the Infectious Diseases and Acute Leukemia Working Parties
Authors: Olaf Penack, Gloria Tridello, Jeniffer Hoek, Gerard Socie, Didier Blaise, Jakob Passweg, Patrice Chevallier, Charles Craddock, Noel Milpied, Hendrik Veelken, Johan Maertens, Per T. Ljungman, Jan J. Cornelissen, Anne Thiebaut-Bertrand, Bruno Lioure, Mauricette Michallet, Simona Iacobelli, Arnon Nagler, Mohamad Mohty, Simone Cesaro
Journal: Blood (2014)
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations
Authors: Gian Matteo Rigolin, Elena Saccenti, Cristian Bassi, Laura Lupini, Francesca Maria Quaglia, Maurizio Cavallari, Sara Martinelli, Luca Formigaro, Enrico Lista, Maria Antonella Bardi, Eleonora Volta, Elisa Tammiso, Aurora Melandri, Antonio Urso, Francesco Cavazzini, Massimo Negrini, Antonio Cuneo
Journal: Journal of Hematology & Oncology (2016)

In chronic lymphocytic leukemia (CLL), next-generation sequencing (NGS) analysis represents a sensitive, reproducible, and resource-efficient technique for routine screening of gene mutations. We performed an extensive biologic characterization of newly diagnosed CLL, including NGS analysis of 20 genes frequently mutated in CLL and karyotype analysis to assess whether NGS and karyotype results could be of clinical relevance in the refinement of prognosis and assessment of risk of progression. The genomic DNA from peripheral blood samples of 200 consecutive CLL patients was analyzed using Ion Torrent Personal Genome Machine, a NGS platform that uses semiconductor sequencing technology. Karyotype analysis was performed using efficient mitogens. Mutations were detected in 42.0 % of cases with 42.8 % of mutated patients presenting 2 or more mutations. The presence of mutations by NGS was associated with unmutated IGHV gene (p = 0.009), CD38 positivity (p = 0.010), risk stratification by fluorescence in situ hybridization (FISH) (p < 0.001), and the complex karyotype (p = 0.003). A high risk as assessed by FISH analysis was associated with mutations affecting TP53 (p = 0.012), BIRC3 (p = 0.003), and FBXW7 (p = 0.003) while the complex karyotype was significantly associated with TP53, ATM, and MYD88 mutations (p = 0.003, 0.018, and 0.001, respectively). By multivariate analysis, the multi-hit profile (≥2 mutations by NGS) was independently associated with a shorter time to first treatment (p = 0.004) along with TP53 disruption (p = 0.040), IGHV unmutated status (p < 0.001), and advanced stage (p < 0.001). Advanced stage (p = 0.010), TP53 disruption (p < 0.001), IGHV unmutated status (p = 0.020), and the complex karyotype (p = 0.007) were independently associated with a shorter overall survival. At diagnosis, an extensive biologic characterization including NGS and karyotype analyses using novel mitogens may offer new perspectives for a better refinement of risk stratification that could be of help in the clinical management of CLL patients.
Primary Oral Cavity Lymphomas. Features of 29 Patients Assisted at Oncology Hospital Marie Curie, Buenos Aires Argentina.
Authors: Marta O. Dragosky, Nelly Frascino, Susana Alcaraz, Isabel Annetta, Laura Devoto, Patricia Luchetta, Marisa Marquez, Carmen Giaco, Karina Gallo, Gabriela Acosta, Elsa Alcoba, Jorgelina Stagnaro, Laura Guerrero
Journal: Blood (2006)
Association of Intervals Between Neoadjuvant Chemoradiation and Surgical Resection With Pathologic Complete Response and Survival in Patients With Esophageal Cancer
Authors: Kelly R. Haisley, Amy E. Laird, Nima Nabavizadeh, Ken M. Gatter, John M. Holland, Gina M. Vaccaro, Charles R. Thomas, Paul H. Schipper, John G. Hunter, James P. Dolan
Journal: JAMA Surgery (2016)

<h3>Importance</h3> Pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (CRT) may be a clinical prognostic marker of superior outcomes. In patients with esophageal cancer, pCR is associated with increased survival. While mechanisms for increasing the likelihood of pCR remain unknown, in other solid tumors, higher rates of pCR have been associated with longer time intervals between CRT completion and surgical procedures. <h3>Objective</h3> To determine the association between time intervals from the completion of CRT to surgical procedure with rates of pCR in patients with esophageal cancer. <h3>Design, Setting, and Participants</h3> A prospectively maintained multidisciplinary foregut database was reviewed for consecutively enrolled patients with esophageal cancer from January 2000 to July 2015 presenting for surgical evaluation at a single National Cancer Institute–designated cancer center within a quaternary academic medical center. <h3>Interventions</h3> Included patients successfully completed neoadjuvant CRT followed by esophagectomy. <h3>Main Outcomes and Measures</h3> Rate of pCR by logistic regression based on a categorized time interval (ie, 0 to 42, 43 to 56, 57 to 70, 71 to 84, 85 to 98, and 99 or more days) from the completion of CRT to surgical resection, adjusted for clinical stage, demographic information, and CRT regimen. <h3>Results</h3> Of the 234 patients who met inclusion criteria, 191 (81.6%) were male, and the median (range) age was 64 (58-70) years; 206 (88.0%) were diagnosed as having adenocarcinoma, and 65 (27.9%) had a pCR. Patients in the 85 to 98–day group had significantly increased odds of a pCR compared with other groups (odds ratio, 5.46; 95% CI, 1.16-25.68;<i>P</i> = .03). No significant differences in survival were seen between time groups overall or among patients with residual tumor. <h3>Conclusions and Relevance</h3> This study suggests that a time interval of 85 to 98 days between CRT completion and surgical resection is associated with significantly increased odds of a pCR in patients with esophageal cancer. No adverse association with survival was detected as a result of delaying resection, even in patients with residual tumor.
Characterization of 22 cases of marginal zone B-cell lymphoma with trisomy 3
Authors: J Dierlamm, L Michaux, Iwona Wlodarska, S Pittaluga, W Zeller, Michel Stul, A Criel, José Thomas, Marc Boogaerts, P Delaere, Jean-Jacques Cassiman, Christiane Peeters, C Mecucci, Herman Van den Berghe
Journal: Annals of Oncology (1996)
Gelatin-based Hydrogel Degradation and Tissue Interaction <i>in vivo</i>: Insights from Multimodal Preclinical Imaging in Immunocompetent Nude Mice
Authors: Christoph Tondera, Sandra Hauser, Anne Krüger-Genge, Friedrich Jung, Axel T. Neffe, Andreas Lendlein, Robert Klopfleisch, Jörg Steinbach, Christin Neuber, Jens Pietzsch
Journal: Theranostics (2016)

Hydrogels based on gelatin have evolved as promising multifunctional biomaterials.Gelatin is crosslinked with lysine diisocyanate ethyl ester (LDI) and the molar ratio of gelatin and LDI in the starting material mixture determines elastic properties of the resulting hydrogel.In order to investigate the clinical potential of these biopolymers, hydrogels with different ratios of gelatin and diisocyanate (3-fold (G10_LNCO3) and 8-fold (G10_LNCO8) molar excess of isocyanate groups) were subcutaneously implanted in mice (uni-or bilateral implantation).Degradation and biomaterial-tissue-interaction were investigated in vivo (MRI, optical imaging, PET) and ex vivo (autoradiography, histology, serum analysis).Multimodal imaging revealed that the number of covalent net points correlates well with degradation time, which allows for targeted modification of hydrogels based on properties of the tissue to be replaced.Importantly, the degradation time was also dependent on the number of implants per animal.Despite local mechanisms of tissue remodeling no adverse tissue responses could be observed neither locally nor systemically.Finally, this preclinical investigation in immunocompetent mice clearly demonstrated a complete restoration of the original healthy tissue.
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma
Authors: Nikhil C. Munshi, Herve Avet-Loiseau, Andy C. Rawstron, Roger G. Owen, J. Anthony Child, Anjan Thakurta, Paul Sherrington, Mehmet Kemal Samur, Anna Georgieva, Kenneth C. Anderson, Walter M. Gregory
Journal: JAMA Oncology (2016)

<h3>Importance</h3> Numerous studies have evaluated the prognostic value of minimal residual disease (MRD) in patients with multiple myeloma (MM). Most studies were small and varied in terms of patient population, treatment, and MRD assessment methods. <h3>Objective</h3> To evaluate the utility of MRD detection in patients with newly diagnosed MM. <h3>Data Sources</h3> A Medline search was conducted for articles published in English between January 1990 and January 2016. <h3>Study Selection</h3> Eligible studies reported MRD status and progression-free survival (PFS) or overall survival (OS) in 20 or more patients following treatment. Among 405 articles identified, 21 met the initial eligibility criteria and were included in the analysis. <h3>Data Extraction and Synthesis</h3> Information on patient characteristics, treatment, MRD assessment, and outcomes were extracted using a standard form. <h3>Main Outcomes and Measures</h3> The impact of MRD status on PFS and OS was assessed by pooling data from relevant trials. Data were adjusted to allow for different proportions of patients with MRD in different studies, and analyzed using the Peto method. Forest plots were created based on Cox model analysis. Other prespecified research questions were addressed qualitatively. <h3>Results</h3> Fourteen studies (n = 1273) provided data on the impact of MRD on PFS, and 12 studies (n = 1100) on OS. Results were reported specifically in patients who had achieved conventional complete response (CR) in 5 studies for PFS (n = 574) and 6 studies for OS (n = 616). An MRD-negative status was associated with significantly better PFS overall (hazard ratio [HR], 0.41; 95% CI, 0.36-0.48;<i>P</i> &lt; .001) and in studies specifically looking at CR patients (HR, 0.44; 95% CI, 0.34-0.56;<i>P</i> &lt; .001). Overall survival was also favorable in MRD-negative patients overall (HR, 0.57; 95% CI, 0.46-0.71;<i>P</i> &lt; .001) and in CR patients (HR, 0.47; 95% CI, 0.33-0.67;<i>P</i> &lt; .001). Tests of heterogeneity found no significant differences among the studies for PFS and OS. <h3>Conclusions and Relevance</h3> Minimal residual disease-negative status after treatment for newly diagnosed MM is associated with long-term survival. These findings provide quantitative evidence to support the integration of MRD assessment as an end point in clinical trials of MM.
Disruption of Leukemia/Stroma Cell Interactions by CXCR4 Antagonist AMD3465 Enhances Chemotherapy-Induced Apoptosis in AML.
Authors: Zhihong Zeng, Marina Konopleva, Billie J. Nowak, William Plunkett, Gautam Borthakur, Elihu Estey, Richard Champlin, Gary Bridger, Michael Andreeff
Journal: Blood (2005)
Improved Immune Reconstitution After Bortezomib-Based Acute Graft-Versus-Host Disease Prophylaxis for HLA-Mismatched Unrelated Donor Reduced-Intensity Conditioning Allogeneic Transplantation.
Authors: John Koreth, Kristen E. Stevenson, Haesook T. Kim, Sean McDonough, Maria I. Herrera, Carol G. Reynolds, Gorka Murga, Vincent T. Ho, Corey Cutler, Philippe Armand, Robert J. Soiffer, Joseph H. Antin, Edwin P. Alyea, Jerome Ritz
Journal: Blood (2009)